

Product Description

Pioneering GTPase and Oncogene Product Development since 2010

UBE2A RABBIT PAB

货号: S218811

产品全名: UBE2A 兔多抗

基因符号 UBC2; HHR6A; MRXSN; RAD6A; MRXS30 UNIPROT ID: P49459 (Gene Accession - BC010175)

背景: The modification of proteins with ubiquitin is an important cellular mechanism for targeting abnormal or short-lived proteins for degradation. Ubiquitination involves at least three classes of enzymes: ubiquitin-activating enzymes, ubiquitin-conjugating enzymes, and ubiquitin-protein ligases. This gene encodes a member of the E2 ubiquitin-conjugating enzyme family. This enzyme is required for post-replicative DNA damage repair, and may play a role in transcriptional regulation. Mutations in this gene are associated with mental retardation. Alternative splicing results in multiple transcript variants.

抗原: Fusion protein of human UBE2A

经过测试的应用: ELISA, IHC


推荐稀释比: IHC: 50-300; ELISA: 5000-10000

种属反应性: Rabbit 克隆性: Rabbit Polyclonal


亚型: Immunogen-specific rabbit IgG 纯化: Antigen affinity purification 种属反应性: Human, Mouse

成分: PBS (without Mg2+ and Ca2+), pH 7.4, 150 mM NaCl, 0.05% Sodium Azide and 40% glycerol


研究领域: Epigenetics and Nuclear Signaling, Cell Biology 储存和运输: Store at -20℃. Avoid repeated freezing and thawing




Immunohistochemistry analysis of paraffin embedded Human cervical cancer tissue using 218811(UBE2A Antibody) at a dilution of 1/45(Cell membrane).



In comparision with the IHC on the left, the same paraffin-embedded Human cervical cancer tissue is first treated with the fusion protein and then with 218811(Anti-UBE2A Antibody) at dilution 1/45.



The image on the left is immunohistochemistry of paraffinembedded Human colorectal cancer tissue using 218811(Anti-UBE2A Antibody) at a dilution of 1/45.



In comparision with the IHC on the left, the same paraffin-embedded Human colorectal cancer tissue is first treated with fusion protein and then with D225251(Anti-UBE2A Antibody) at dilution 1/45.



Product Description

Pioneering GTPase and Oncogene Product Development since 2010